| Mr Thomas Joseph Houghtalen, DPT, MTC | |
|
42 Saratoga Road, Scotia, NY 12302 | |
| (518) 399-0062 | |
| (518) 399-4513 |
| Full Name | Mr Thomas Joseph Houghtalen |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 45 Years |
| Location | 42 Saratoga Road, Scotia, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902865629 | NPI | - | NPPES |
| 00762703 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 0067260 (New York) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Physical Therapy Associates Of Schenectady Pc | 9032013420 | 22 |
News Archive
The UK-based Therapy Box has released the first app that allows people who have limited vocal ability or are losing their voices due to ALS and other disabling conditions to replace generic text-to-speech synthesis with a synthesizer based on their own voice. The app breaks new ground via the integration of ModelTalker, a program developed by Tim Bunnell, PhD and colleagues at the Nemours Speech Research Laboratory in Wilmington, DE.
Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).
Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. ("NeedleTech") subsequent to its acquisition by Theragenics on July 28, 2008.
Eli Lilly and Company announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b study in episodic migraine.
› Verified 5 days ago
| Provider Name | Physical Therapy Associates Of Schenectady Pc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1669553376 PECOS PAC ID: 9032013420 Enrollment ID: O20031126000464 |
News Archive
The UK-based Therapy Box has released the first app that allows people who have limited vocal ability or are losing their voices due to ALS and other disabling conditions to replace generic text-to-speech synthesis with a synthesizer based on their own voice. The app breaks new ground via the integration of ModelTalker, a program developed by Tim Bunnell, PhD and colleagues at the Nemours Speech Research Laboratory in Wilmington, DE.
Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).
Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. ("NeedleTech") subsequent to its acquisition by Theragenics on July 28, 2008.
Eli Lilly and Company announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b study in episodic migraine.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Thomas Joseph Houghtalen, DPT, MTC 42 Saratoga Road, Scotia, NY 12302 Ph: (518) 399-0062 | Mr Thomas Joseph Houghtalen, DPT, MTC 42 Saratoga Road, Scotia, NY 12302 Ph: (518) 399-0062 |
News Archive
The UK-based Therapy Box has released the first app that allows people who have limited vocal ability or are losing their voices due to ALS and other disabling conditions to replace generic text-to-speech synthesis with a synthesizer based on their own voice. The app breaks new ground via the integration of ModelTalker, a program developed by Tim Bunnell, PhD and colleagues at the Nemours Speech Research Laboratory in Wilmington, DE.
Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).
Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2009. Consolidated results include the results of NeedleTech Products, Inc. ("NeedleTech") subsequent to its acquisition by Theragenics on July 28, 2008.
Eli Lilly and Company announced today that its investigational medicine for prevention of migraine (LY2951742, a CGRP neutralizing antibody) met the primary endpoint in a Phase 2b study in episodic migraine.
› Verified 5 days ago
Mrs. Diane E Bonesteel, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 42 Saratoga Rd, Scotia, NY 12302 Phone: 518-399-0062 Fax: 518-399-4513 | |
Dr. Krystal F Clarke, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 42 Saratoga Rd, Scotia, NY 12302 Phone: 518-399-6861 Fax: 518-399-6864 | |
Mrs. Cynthia Rose Lebel, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 42 Saratoga Rd, Scotia, NY 12302 Phone: 518-399-6861 Fax: 518-399-6864 | |
Lora Larson, PT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 42 Saratoga Rd, Scotia, NY 12302 Phone: 518-399-6861 Fax: 516-399-6864 | |
Mrs. Ann Marie Dawdy, PHYSICAL THERAPIST Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 42 Saratoga Rd, Scotia, NY 12302 Phone: 518-399-6861 Fax: 518-399-6864 | |
Pamela Elizabeth Yunginger, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 42 Saratoga Rd, Scotia, NY 12203 Phone: 518-399-6861 Fax: 518-399-6864 | |
Mrs. Rosemarie Agresta Trigger, PT CSHE Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 42 Saratoga Rd, Scotia, NY 12302 Phone: 518-399-0042 Fax: 518-399-4513 |